
Prevention & Lipids
Blood pressure targets and treatment strategies
Synthesized from 134 evidence-backed clinical questions linked to this topic — 36 supporting the intervention, 42 against the intervention, 10 still contested.
No clear lean — the placed evidence is contested
36
Favor benefit
27% of all
42
Favor harm
31% of all
46 more (34%) still untested — not placed on the axis.
Low certainty on 58% of questions
Does antihypertensive drugs vs placebo improve outcomes in Frailty?
Low Certainty+ Favors benefitantihypertensive drugs vs placebo
7 studies (8,985,214 patients) provide low-certainty evidence for benefit of antihypertensive drugs for the outcome in Frailty.
Does antihypertensive vs placebo improve outcomes in Stroke?
Low Certainty− Favors harmantihypertensive vs placebo
8 studies (5,289,215 patients) provide low-certainty evidence against benefit of antihypertensive for the outcome in Stroke.
Does angiotensin receptor blockers vs placebo improve outcomes in Hypertensive disease?
Low Certainty− Favors harmangiotensin receptor blockers vs placebo
26 studies (3,889,575 patients) provide low-certainty evidence against benefit of angiotensin receptor blockers for the outcome in Hypertensive disease.
Does statin vs placebo improve outcomes in Hypertensive disease?
Low Certainty− Favors harmstatin vs placebo
13 studies (1,558,581 patients) provide low-certainty evidence against benefit of statin for the outcome in Hypertensive disease.
Does metoprolol vs propranolol improve outcomes in Hypertensive disease?
Low Certainty− Favors harmmetoprolol vs propranolol
6 studies (1,051,130 patients) provide low-certainty evidence against benefit of metoprolol for the outcome in Hypertensive disease.
Does diuretics vs placebo improve outcomes in Hypertensive disease?
Low Certainty− Favors harmdiuretics vs placebo
26 studies (903,774 patients) provide low-certainty evidence against benefit of diuretics for the outcome in Hypertensive disease.
Does antihypertensives vs placebo improve outcomes in Hypertensive disease?
Insufficient~ Mixed resultsantihypertensives vs placebo · Cardiac Output
452 studies (266,807,266 patients) provide insufficient evidence with mixed findings regarding antihypertensives for Cardiac Output in Hypertensive disease.
Does angiotensin converting enzyme inhibitor vs angiotensin receptor blocker improve outcomes in Hypertensive disease?
Insufficient~ Mixed resultsangiotensin converting enzyme inhibitor vs angiotensin receptor blocker
10 studies (7,152,153 patients) provide insufficient evidence with mixed findings regarding angiotensin converting enzyme inhibitor for the outcome in Hypertensive disease.
Does amlodipine vs chlorthalidone improve outcomes in Hypertensive disease?
Insufficient~ Mixed resultsamlodipine vs chlorthalidone
8 studies (136,774 patients) provide insufficient evidence with mixed findings regarding amlodipine for the outcome in Hypertensive disease.
Does antihypertensive drugs vs diuretic improve outcomes in Hypertensive disease?
Insufficient~ Mixed resultsantihypertensive drugs vs diuretic
6 studies (7,903,740 patients) provide insufficient evidence with mixed findings regarding antihypertensive drugs for the outcome in Hypertensive disease.
Emerging evidence with 100 primary claims
Spontaneous termination of ventricular fibrillation
Heart — Calabrò M — Jan 2004
The use of pindolol in the treatment of essential hypertension: a multi-centre assessment
Current Medical Research and Opinion — Blowers A — Jan 1976
Resistant hypertension: baroreflex stimulation as a new tool
Nephrology Dialysis Transplantation — Menne J — Dec 2012
Rebuttal from Markus P. Schlaich, Yusuke Sata and Murray D. Esler
The Journal of Physiology — Schlaich M — Sep 2014
High fitness levels attenuate the increased risk of cardiovascular deaths in individuals with high systolic blood pressure
European Journal of Preventive Cardiology — Laukkanen J — Mar 2023
Vascular Reactivity in the Pathogenesis of Spontaneous Hypertension
Clinical Science — Berecek K — Dec 1979
Voltage-dependent N-type Ca2+ channels in endothelial cells contribute to oxidative stress-related endothelial dysfunction induced by angiotensin II in mice
Biochemical and Biophysical Research Communications — Nishida M — Mar 2013
EFFECTS OF STRESSFUL LIFE EVENTS IN YOUNG BLACK MEN WITH HIGH BLOOD PRESSURE
Han H — Jan 2006
Arterial alterations in hypertension with a disproportionate increase in systolic over diastolic blood pressure
Journal of Hypertension — Safar M — Sep 1996
Ambulatory Pulse Pressure and Progression of Albuminuria in Type 2 Diabetes
Hypertension — Knudsen S — Jul 2006
Prevention of Hypertension and Cardiovascular Diseases
Hypertension — Kokubo Y — Jan 2014
Association between age at onset of overweight and risk of hypertension across adulthood
Heart — Li W — Feb 2022
The evidence sections above show what the literature supports; this is what the field is still arguing about. Open a debate for the camps, the named voices, and the vote.
Follow this topic to get a weekly “what changed” evidence digest and alerts when journal clubs schedule sessions on it.
Hypertension management (also known as HTN, high blood pressure, BP management). Blood pressure targets and treatment strategies
As of 2026-09-09, the scientific consensus on Hypertension management is emerging. Emerging evidence with 100 primary claims Based on 100 analyzed claims across Synapse's enriched corpus, the evidence shows.
This evidence brief synthesizes Synapse's enriched cardiology corpus; cite as synapsesocial.com/topics/hypertension-management.
Deterministic synthesis from Synapse's enriched corpus — 57 words. No AI-generated novel content; every figure is sourced from the underlying paper, guideline, or trial record linked on this page.
Explore every Hypertension management paper on Synapse with AI-enriched clinical evidence, PICO analysis, and methodology classification.
Search Hypertension management papersPowered by Synapse — AI-enriched analysis of 600,000+ peer-reviewed papers